Cascade Oncogenics (US) licenses cyclin cancer marker
This article was originally published in Clinica
Cascade Oncogenics (US) has licensed the diagnostic rights to cyclin E from the Fred Hutchinson Cancer Center, Seattle. Cascade intends to use the cell cycle regulator to develop a staging and prognosis test for breast cancer. The technology for cyclin E is co-owned by the Fred Hutchinson Center and Rockefeller University.